Compare Hasbro, Inc. (HAS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Summit Therapeutics Inc — how do they compare? Hasbro, Inc. trades at $96 (market cap $13.69B), while Summit Therapeutics Inc trades at $15.25 (market cap $12.06B). The key difference: Hasbro, Inc. and Summit Therapeutics Inc are close in size by market cap, and Hasbro, Inc. pays a 2.89% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HAS | SMMT | |
|---|---|---|
Market Cap | $13.69B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $26.98 |
52-Week Low | $70.95 | $12.55 |
Enterprise Value | $15.88B | $11.39B |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $94.49, up 1.04% today, with strong technical and fundamental momentum. The stock exhibits a bullish trend, supported by consecutive earnings beats in Q4 2025, Q1 2026, and Q2 2026. Recent news highlights growth in adult-focused segments like Magic: The Gathering, with Q2 2026 revenue up 16% year-over-year. Valuation metrics show a P/E of 17.27 and P/S of 2.77, while analyst consensus is bullish with a $104.90 price target.
The outlook for Hasbro is positive, driven by IP strength and digital gaming growth, but risks include margin pressures from tariffs and high debt levels. Institutional buying and a 51.52% buy rating from analysts support upside potential, though investors should monitor execution risks and macroeconomic headwinds. The stock's current price is within 5% of its 52-week high, indicating strong near-term momentum.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
